Thus, there is a potential risk of toxicity in the use of STAT3 inhibitors associated with inhibiting mitochondrial function, which may be unacceptable, especially in non-cancer indications, such as inflammation and fibrosis. The gene discussed is STAT3; the disease is cancer.